AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05101447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
Study NCT05101447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
Study NCT05106127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-007
Description: A Repurposed Drug
Study NCT05106127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.
Study NCT05106127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
Study NCT04802330 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
Study NCT04867928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax+azacitidine
Description: subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
Study NCT06211881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chi-GVM
Description: Chi-GVM regimen (every 21 days is a treatment cycle):~Chidamide 20 mg orally;gemcitabine 1g/m2, twice a week, intravenous infusion on day 1, vinorelbine 20 mg/m2, infusion on day 1; Mitoxantrone Hydrochloride Liposome12 mg/m2, intravenous infusion on day 1; Chidamide maintenance therapy: 20 mg orally twice a week/28 days/cycle.
Study NCT04743115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS HH 002.SA
Description: The Dose Escalation Part is a 3+3 design dose escalation study to determine the MTD of BS HH 002.SA in up to approximately 30 patients with the protocol AML indication or high risk MDS. Cohorts of 3 patients will be sequentially assigned to receive BS HH 002.SA at escalating DLs following the standard 3+3 dose escalation design, with 3 to 6 patients at each DL.~Cohort Expansion Part: Following determination of the MTD, the study will continue at the MTD and/or a lower DL
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlunestrant
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinidine
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally.
Study NCT05444556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally.
Study NCT05086185 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Kalemic Response to Orange Juice
Description: 100% pulp-free orange juice
Study NCT05086185 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Kalemic Response to Orange Juice with Fiber
Description: 100% pulp-free orange juice with psyllium-based fiber added
Study NCT05633563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimetazidine
Description: Oral intake of capsules
Study NCT05633563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral intake of capsules
Study NCT04608981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Description: Steroidal anti-inflammatory drug as a preoperative medication
Study NCT04608981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50mg Tab
Description: Non-steroidal anti-inflammatory drug as a preoperative medication
Study NCT04608981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch
Study NCT04129593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Awakening - Natural Waking
Description: subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
Study NCT04129593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snooze - Natural waking
Description: subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
Study NCT04907682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin iv
Description: 100 mg/kg Day 1 (dose is divided: 2/3 stat, 1/3 8 hours later, maximum dose is 7g/day), then 25 mg/kg days 2-7, 12.5 mg/kg days 8-10
Study NCT04907682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Day 1 2400mg(H0)-2400mg(H8)-1200mg(H16), Day 2-10 1200mg twice daily
Study NCT05306964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive UFnet Rate Strategy
Description: In the restrictive group, the UFnet rate will be titrated between 0.5-1.5 mL/kg/h and maintained throughout fluid removal.
Study NCT05306964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liberal UFnet Rate Strategy
Description: In the liberal group, the UFnet rate will be titrated between 2.0-5.0 mL/kg/h and maintained throughout fluid removal.
Study NCT06062654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital-assisted Rehabilitation
Description: Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
Study NCT06062654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-assisted Rehabilitation
Description: Patients are assisted by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition and abduction.
Study NCT06062654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Rehabilitation
Description: Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
Study NCT06062654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Rehabilitation
Description: Patients were educated by a physical therapist to perform commuting exercises and active and passive mobilization of the glenohumeral joint in anterior elevation, external rotation, internal rotation, retroposition, and abduction, which they perform at home independently.
Study NCT04777617 — intervention group
Intervention type: OTHER
Intervention: DD-cfDNA
Description: We are obtaining samples for donor derived cell free DNA in an observational manner. There is no intervention in this study
Study NCT04467749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension Wheel
Description: Participants will be given a pair of Spinergy or Loopwheels to use during the 12-week intervention period. The Spinergy wheels consist of a lightweight carbon fiber material with natural shock absorbing properties. Loopwheels offer a rigid rim, a mid-wheel shock absorbing hub and three in-wheel loops that work as a self-correcting system when encountering uneven ground.
Study NCT05588856 — intervention group
Intervention type: OTHER
Intervention: In depth Interview
Description: In depth Interviews
Study NCT06076681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: On Days 1 to 14, all subjects in each group received TNP-2198 capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
Study NCT06076681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: On Days 1 to 14, all subjects in each group received rabeprazole within 30 minutes before breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes before breakfast.
Study NCT06076681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: On Days 1 to 14, all subjects in each group received Amoxicillin capsule within 30 minutes after breakfast and dinner (BID) for 14 consecutive days. On Day 15, the subjects were only administered once within 30 minutes after breakfast.
Study NCT04026464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Ibuprofen
Description: The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
Study NCT04026464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ibuprofen + Oral Acetaminophen
Description: The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen \[160 mg/5ml concentration\] every 6 hours for a total of 12 doses.
Study NCT05342961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinous balloon dilatation catheter (Plastic-Blade)
Description: To treat Coronary artery disease
Study NCT05342961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinous balloon dilatation catheter(lacrosse NSE)
Description: To treat Coronary artery disease
Study NCT06417840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT)
Description: N-trans-caffeoyltyramine (NCT) and N-trans-feruloyltyramine (NFT) derived via synthetic biology (i.e., fermentation using a recombinant microorganism) to provide a high purity (>85%) form of these compounds that are structurally identical to their naturally occurring counterparts. All ingredients in the encapsulated final test article, including the NCT and NFT, are manufactured under food GMPs and are of suitable quality for use in food, dietary supplements, and specialty nutrition products.
Study NCT06417840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study NCT06255327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I COUGH care program
Description: The I COUGH program, initiated 10 hours after surgery, emphasizes the following elements:~Incentive spirometry: Encouraging patients to use the Flow-IS device ten times every two hours for three days.~Coughing and deep breathing: Participants should perform 3-5 coughs and deep breaths every 2 hours for 3 days.~Oral care: Brushing teeth and using mouthwash twice daily between 8:00 a.m. and 8:00 p.m. Mouth brushes should be sterile, and non-alcoholic mouthwash is recommended.~Understanding (education): Patients and their relatives receive instructions on the care program and steps to follow.~Getting out of bed: Patients are encouraged to sit in a chair at least once and walk at least 3 times per day in the room and corridor with assistance as needed.~Head-of-bed elevation: Keeping the head of the bed elevated more than 30 degrees.
Study NCT05363371 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Minds and Mentors
Description: Participants will be randomized into Minds and Mentors to attend weekly group therapy sessions for 12 week. The mindfulness-based relapse prevention therapy intervention will be led by a licensed counselor for eights weeks followed up by four additional sessions led by a certified recovery support specialist (peer mentor).
Study NCT05363371 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Twelve Step Intervention Group
Description: Participants will be randomized to the Twelve Step Intervention Group to attend weekly group therapy sessions for 12 week. The twelve step intervention group will be led by a licensed counselor.
Study NCT04936607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized hydration strategy
Description: In the experimental group, NS infusion rate will be adjusted based on LVEDP for the whole duration of the procedure (\<13 mmHg: 5 ml/kg/h; 13-18 mmHg: 3 ml/kg/h; >18 mmHg: 1.5 ml/kg/h), or for one hour, whichever is the longest. After the procedure, and for a duration of 4 hours, the hydration rate will be adjusted based on the (contrast volume:estimated glomerular filtration rate (eGFR)) ratio, according to the following scheme: 1.5 ml/kg/h if contrast volume/eGFR ratio \<2.0; 3 ml/kg/h for contrast volume/eGFR ratio 2.0-2.9; 5 ml/kg/h for contrast volume/eGFR ratio ≥3.0.
Study NCT04936607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: In the control group, infusion rate will be of 1.5 ml/kg/h during the procedure, and for the 4 following hours.
Study NCT06239584 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsies performed via bronchoscopy
Description: An additional amount of lung tumor tissue will be collected compared to that normally obtained as standard clinical practice, during bronchoscopy, al in order to increase the probability of successful generation of organoids
Study NCT05946655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin + Metronidazole
Description: Ofloxacin 2x200mg orally for 10 days + Metronidazole 1x500 mg vaginally for 10 days
Study NCT05164081 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
Description: Hospitals are cluster-randomized to either arm for 2 years and then cross-over to the other arm for another 2 years.
Study NCT05164081 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
Description: antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
Study NCT05529498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate paced continuous gait training
Description: walking continuously for 20 minutes at a moderate pace
Study NCT05529498 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval gait training
Description: 20 minutes of interspersing 30 seconds of fast walking with 1 minute of rest
Study NCT04853758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.
Study NCT04853758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.
Study NCT05569434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
Study NCT06544174 — intervention group
Intervention type: OTHER
Intervention: Percutaneous Coronary Intervention of CTO
Description: CTO-PCI is a procedure of interventional cardiology attempting revascularisation of the CTO
Study NCT06298084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: 5.6 mg/kg every 21 days
Study NCT06298084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 100 mg b.i.d PO days 8-14 every 21 days
Study NCT05638165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCP112
Description: The first two subjects for sentinel dosing are randomly assigned to either the test drug or placebo in a 1:1 ratio. After safety and tolerability were reviewed for sentinel participants up to 24 hours after dosing, the subsequent 7 subjects are randomized to the remaining treatment allocations, with 5 subjects to the test drug and 2 to the placebo.
Study NCT06276322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low back pain group
Description: The low back pain group will be evaluated the kinematics of all spine segments in 3 planes while performing the tasks that patients with chronic low back pain often describe as painful in their daily lives such as walking, stepping up, standing up, bending and lifting. Using Inertial Measurement Sensors that provide valid and reliable will evaluate the kinematics of all spine
Study NCT06276322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy group
Description: Low back pain kinematics compare them with asymptomatic kontrols
Study NCT06176261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan
Description: Antibody-drug conjugate, 100 mg single-use vial, via intravenous infusion per protocol.
Study NCT06413602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During AIH, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles. One cycle involves breathing air with lower oxygen concentration (9-10% oxygen) for 30 and 90 seconds, followed by breathing normal room air (21% oxygen) for a similar duration. This cycle is repeated 15 times in one session. Blood oxygen and heart rate are monitored throughout.
Study NCT06413602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: During NMES, participants will receive electrical stimulation to the common peroneal nerve. Stimulation will be done with a 50% duty cycle, duration of 0.5-1ms for each pulse and a frequency 25-40 Hz. The stimulus intensity will be adjusted to produce approximately 50% of the maximum M-wave (compound muscle action potential) for each participant.
Study NCT06525415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DCE MRI
Description: the recruited patients should complete pre- and post-operative DCE MRI workshops
Study NCT06429150 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Infusion of multi-CAR-T cells
Study NCT05036174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 5%
Description: Diphenhydramine 5% ointment
Study NCT05036174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to diphenhydramine 5% ointment
Study NCT05246917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Description: To perform hand sewn anastomosis (either end to end or Kono-s) during the reconstruction face of ileocolic resection
Study NCT05421741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic coated intramedullary Nail
Description: Antibiotic coated intramedullary nail:~A mixture of 40gm bag of acrylic cement, antibiotic powder (Vancomycin 2gm) and 560mg gentamicin liquid. The intramedullary is coated with the mixture using a cement gun tube.
Study NCT05421741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intramedullary Nail
Description: Standard Intramedullary Nail
Study NCT06244004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Undergo SOC ADT
Study NCT06244004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Undergo SOC ADT
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06244004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT06244004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotoxic Chemotherapy
Description: Receive SOC cytotoxic chemotherapy
Study NCT06244004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotoxic Chemotherapy
Description: Receive SOC cytotoxic chemotherapy